Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05919238 · ClinicalTrials.gov registry record · Phase 1

Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma

A Phase 1 study of Locally Advanced Unresectable Pancreatic Adenocarcinoma, sponsored by Impact Biotech.

Recruiting
Registry status
Phase 1
Development phase
30
Enrollment target
2
Study locations

NCT05919238 is a Phase 1 study of Locally Advanced Unresectable Pancreatic Adenocarcinoma that is actively recruiting participants, run by Impact Biotech. The registered enrollment target is 30 participants. The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05919238, a Phase 1 study of Locally Advanced Unresectable Pancreatic Adenocarcinoma, is actively recruiting participants, sponsored by Impact Biotech.

RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
2
Study locations

Study Summary

This is a prospective, multicenter, non-randomized, open label light dose escalation phase I trial to evaluate the safety and preliminary efficacy of Padeliporfin vascular targeted photodynamic therapy (VTP) applied via endovascular fiber placement within a dilatation catheter, through the target artery(superior mesenteric artery (SMA), celiac artery (CA) or common hepatic artery (CHA)). The investigators will evaluate safety and preliminary efficacy of Padeliporfin VTP administered endovascularly using light dose escalation.

Interventions

  • COMBINATION_PRODUCT Padeliporfin Vascular Targeted Photodynamic (VTP) therapy

Study Locations (2)

California

  • City of Hope - Duarte
  • University of California Irvine - Irvine

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-05-15
Est. Completion 2026-10-30
Phase Phase 1

Sponsor

Impact Biotech

2 total trials

What the Registry Record Tells You About NCT05919238

The ClinicalTrials.gov registry entry for NCT05919238 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Impact Biotech, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Locally Advanced Unresectable Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Padeliporfin Vascular Targeted Photodynamic (VTP) therapy is the first listed.

NCT05919238 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05919238 about?

NCT05919238 is a clinical study titled "Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma". This is a prospective, multicenter, non-randomized, open label light dose escalation phase I trial to evaluate the safety and preliminary efficacy of Padeliporfin vascular targeted photodynamic therapy (VTP) applied via endovascular fiber placement within a dilatation catheter, through the target ar...

What is the current status of trial NCT05919238?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2024-05-15. Estimated completion is 2026-10-30.

What conditions does trial NCT05919238 study?

This clinical trial studies the following conditions: Locally Advanced Unresectable Pancreatic Adenocarcinoma.

What interventions are being tested in trial NCT05919238?

The interventions under investigation include: Padeliporfin Vascular Targeted Photodynamic (VTP) therapy (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT05919238?

This trial is sponsored by Impact Biotech, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05919238 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Locally Advanced Unresectable Pancreatic Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.